Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK14 | Q16539 | 6/20 | 0.53 |
| ▸ | BRAF | P15056 | 4/20 | 0.43 |
| ▸ | SCARB1 | Q8WTV0 | 4/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16138966 | 0.86 | MAPK14 (0.53) | MAPK14BRAFSCARB1 | |
| SCHEMBL19054703 | 0.86 | MAPK14 (0.55) | MAPK14BRAFSCARB1 | |
| SCHEMBL16151034 | 0.84 | MAPK14 (0.52) | MAPK14BRAFSCARB1 | |
| SCHEMBL689712 | 0.84 | MAPK14 (0.51) | MAPK14BRAFSCARB1 | |
| SCHEMBL1846611 | 0.84 | MAPK14 (0.63) | MAPK14BRAFSCARB1 | |
| Hydrochloric Acid SCHEMBL1301953 | 0.83 | MAPK14 (0.50) | MAPK14BRAFSCARB1 | |
| SCHEMBL19050446 | 0.82 | MAPK14 (0.49) | MAPK14BRAFSCARB1 | |
| SCHEMBL18461715 | 0.82 | MAPK14 (0.50) | MAPK14BRAFSCARB1 | |
| SCHEMBL13130341 | 0.82 | MAPK14 (0.49) | MAPK14BRAFSCARB1 | |
| SCHEMBL12677001 | 0.82 | MAPK14 (0.52) | MAPK14BRAFSCARB1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 22 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2023237759-A1 | DIHYDRO[1,8]NAPHTHYRIDIN-7-ONE AND PYRIDO[3,2-B][1,4]OXAZIN-3-ONE FOR USE IN TREATING CANCER, AND METASTASES IN PARTICULAR | ANAGENESIS BIOTECHNOLOGIES (FR) | 2023-12-14 | — | — | WO | disclosed |
| EP-4289427-A1 | DIHYDRO[1,8]NAPHTHYRIDIN-7-ONE AND PYRIDO[3,2-B][1,4]OXAZIN-3-ONE FOR USE IN TREATING CANCER, AND METASTASES IN PARTICULAR. | Anagenesis Biotechnologies (FR) | 2023-12-13 | — | — | EP | disclosed |
| EP-2981526-B1 | INTERMEDIATES USEFUL IN THE PREPARATION OF NAPHTHYLUREA DERIVATIVES USEFUL AS KINASE INHIBITORS | OXULAR ACQUISITIONS LTD (GB) | 2021-11-03 | — | — | EP | disclosed |
| US-9822076-B2 | Kinase inhibitor | RESPIVERT LIMITED (GB) | 2017-11-21 | — | — | US | disclosed |
| US-9822076-B2 | Kinase inhibitor | RESPIVERT LIMITED (GB) | 2017-11-21 | — | — | US | disclosed |
| WO-2017108736-A1 | N-[3-(3-{4-[[1,2,4]TRIAZOLO[4,3-A]PYRIDIN-6-YLOXY]-1,2,3,4-TETRAHYDRO-NAPHTHALEN-1-YL} -UREIDO)-PHENYL]-METHANESULFONAMIDE DERIVATIVES AND THEIR USE AS P38 MAPK INHIBITORS | CHIESI FARMACEUTICI S.P.A. (IT) | 2017-06-29 | — | — | WO | disclosed |
| US-20170029378-A1 | KINASE INHIBITOR | OXULAR ACQUISITIONS LIMITED (GB) | 2017-02-02 | — | — | US | disclosed |
| US-20170029378-A1 | KINASE INHIBITOR | OXULAR ACQUISITIONS LIMITED (GB) | 2017-02-02 | — | — | US | disclosed |
| US-9499486-B2 | Kinase inhibitor | RESPIVERT LIMITED (GB) | 2016-11-22 | — | — | US | disclosed |
| US-9499486-B2 | Kinase inhibitor | RESPIVERT LIMITED (GB) | 2016-11-22 | — | — | US | disclosed |
| US-8927563-B2 | Kinase inhibitor | RESPIVERT LIMITED (GB) | 2015-01-06 | — | — | US | disclosed |
| US-8927563-B2 | Kinase inhibitor | RESPIVERT LIMITED (GB) | 2015-01-06 | — | — | US | disclosed |
| US-20140296271-A1 | KINASE INHIBITOR | TOPIVERT PHARMA LIMITED (GB) | 2014-10-02 | — | — | US | disclosed |
| US-20140296271-A1 | KINASE INHIBITOR | TOPIVERT PHARMA LIMITED (GB) | 2014-10-02 | — | — | US | disclosed |
| US-8778929-B2 | Substituted heteroaryl inhibitors of B-RAF | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2014-07-15 | — | — | US | disclosed |
| US-8653087-B2 | Pyrido [5, 4-D] pyrimidines as cell proliferation inhibitors | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2014-02-18 | — | — | US | disclosed |
| US-20120094975-A1 | PYRIDO [5, 4-D] PYRIMIDINES AS CELL PROLIFERATION INHIBITORS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2012-04-19 | — | — | US | disclosed |
| US-20110312939-A1 | NEW CHEMICAL COMPOUNDS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2011-12-22 | — | — | US | disclosed |
| EP-1725544-B1 | 3-[4-HETEROCYCLYL-1,2,3-TRIAZOL-1-YL]-N-ARYL-BENZAMIDES AS INHIBITORS OF THE CYTOKINES PRODUCTION FOR THE TREATMENT OF CHRONIC INFLAMMATORY DISEASES | BOEHRINGER INGELHEIM PHARMA (US) | 2009-05-27 | — | — | EP | disclosed |
| EP-1887003-A1 | 3-[4-HETEROCYCLYL -1,2,3-TRIAZOL-1-YL]-N-ARYL-BENZAMIDES AS INHIBITORS OF THE CYTOKINES PRODUCTION FOR THE TREATMENT OF CHRONIC INFLAMMATORY DISEASES | Boehringer Ingelheim Pharmaceuticals, Inc. (US) | 2008-02-13 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140296271-A1 | KINASE INHIBITOR | LCK, SYK, FYN | MAPK14 41/4885BRAF 112/4885SCARB1 1445/4885 |
| US-20170029378-A1 | KINASE INHIBITOR | SYK, BTK, LYN | MAPK14 37/4885BRAF 104/4885SCARB1 1038/4885 |
| US-20110312939-A1 | NEW CHEMICAL COMPOUNDS | CCNA1, CCNT1, MKI67 | MAPK14 2402/4885BRAF 433/4885SCARB1 2226/4885 |
| US-20120094975-A1 | PYRIDO [5, 4-D] PYRIMIDINES AS CELL PROLIFERATION INHIBITORS | CCNT1, CCNA1, CCND1 | MAPK14 1786/4885BRAF 1032/4885SCARB1 4096/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.